HER2 medicines before surgery for resectable esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests two targeted medicines, trastuzumab and pertuzumab (HER2-blocking drugs), given before surgery for HER2-positive esophageal or stomach-esophagus junction cancer. The goal is to shrink the tumor and improve how well surgery works and outcomes after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have esophageal or gastroesophageal junction cancer proven by biopsy (adenocarcinoma).
- Your tumor is HER2-positive (either strong HER2 staining, or weaker staining plus a special HER2 test).
- Your cancer is considered operable (can be surgically removed) by the study team’s multidisciplinary review.
- You’re 18 or older, and your overall health score is 0–1 on the ECOG scale.
- Your blood counts and organ function (kidneys, liver, bone marrow) are adequate, and your heart pumping function is strong (LVEF ≥55%).
- You can attend follow-up visits at the treatment center and you provide signed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding pembrolizumab to standard trastuzumab and chemotherapy for people with HER2-positive stomach or esophageal cancer that can be fully removed with surgery. The goal is to see if this combination improves outcomes before and after surgery.
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This trial tests two new investigational drugs (SHR-A1811 and SHR-A1701) given before surgery for stomach cancer that is HER2-positive and may respond to immunotherapy. The goal is to see if these drugs can shrink the tumor or improve outcomes when combined with surgery.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This trial tests a combination of three medicines (immunotherapy plus two chemotherapy drugs) given before surgery to shrink esophageal cancer. The goal is to make the tumor smaller and easier to remove completely, potentially improving the chance of a cure.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.